Please use this identifier to cite or link to this item:
Title: Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Author: Cruz Jentoft, Alfonso J.
Romero Yuste, Susana
Chamizo Carmona, Eugenio
Nolla Solé, Joan Miquel
Keywords: Artritis reumatoide
Malalties immunitàries
Rheumatoid arthritis
Immunologic diseases
Issue Date: 10-Feb-2021
Publisher: Springer Nature
Abstract: Introduction: Sarcopenia is defined by a loss of muscle mass and function associated with mortality, decreased physical performance, falls, and disability. Since chronic inflammation and decreased physical activity are risk factors for developing sarcopenia, it is critical to assess the role of sarcopenia in immune-mediated rheumatic diseases (IMRDs). Moreover, nutritional interventions are emerging as key modifiable and affordable options to improve physical performance in sarcopenia. Objective: The aim of this review is to critically summarize current information on the evidence linking nutritional interventions and sarcopenia in IMRDs. Methods: The search and selection of articles was performed in Medline,, Google Scholar, Cochrane Library, Epistemonikos, and Trip Database. The results were clustered into three areas: sarcopenia and IMRDs, sarcopenia and biological disease-modifying antirheumatic drugs (bDMARDs), and nutritional interventions for sarcopenia. Findings: Several cross-sectional studies have shown a higher prevalence of sarcopenia in IMRDs, such as rheumatoid arthritis. Although not fully established, evidence linking sarcopenia and other IMRDs (ankylosing spondylitis and systemic sclerosis) has been also described. For secondary sarcopenia prevention and treatment, bDMARDs' administration proved efficacy in patients with rheumatoid arthritis. Furthermore, there is growing evidence linking nutrition to the prevention and treatment of sarcopenia. Evidence linking unfavourable results in nutritional risk assessment, insufficient intake of protein, vitamin D, antioxidant nutrients, and long-chain polyunsaturated fatty acids and sarcopenia have been reported. Conclusion: Given that sarcopenia and IMRDs have strong links, further research is needed to improve patient care.
Note: Reproducció del document publicat a:
It is part of: Aging Clinical and Experimental Research, 2021
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Cruz-Jentoft2021_Article_SarcopeniaImmune-mediatedRheum.pdf620.12 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons